Drug Profile
MAM 06301
Alternative Names: Beta-aescin - Marinomed Biotechnologie; Beta-escin - Marinomed Biotechnologie; MAM-06.301Latest Information Update: 22 Sep 2021
Price :
$50
*
At a glance
- Originator Marinomed Biotechnologie
- Class Antiallergics
- Mechanism of Action Nitric oxide modulators; Prostaglandin F2alpha receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Allergic asthma; Allergic contact dermatitis; Hypersensitivity
Most Recent Events
- 22 Sep 2021 Discontinued - Phase-II for Allergic contact dermatitis in Germany (Topical)
- 22 Sep 2021 Discontinued - Phase-II for Hypersensitivity in Germany (Topical)
- 22 Sep 2021 Discontinued - Preclinical for Allergic asthma in Austria (PO)